Journal article
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Journal of rheumatology, v 49(7), pp 694-699
15 Apr 2022
PMID: 35428720
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The probability of achieving Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) treatment targets (remission [REM], low disease activity [LDA]) was evaluated following apremilast monotherapy in disease-modifying antirheumatic drug (DMARD)-naïve patients with psoriatic arthritis (PsA) based on baseline disease activity.
This post hoc probability analysis of PALACE 4, a phase III, multicenter, randomized, placebo-controlled study, evaluated shifting across cDAPSA categories from baseline to week 52 and included DMARD-naïve patients receiving apremilast 30 mg BID with available baseline cDAPSA data. Changes in articular/extraarticular manifestations were evaluated in patients with week 52 cDAPSA components. cDAPSA treatment target achievement was assessed in a subgroup with baseline extraarticular PsA manifestations (skin involvement, enthesitis, dactylitis).
Of 175 apremilast-treated patients in the probability analysis, 66.3% were in high disease activity (HDA) and 31.4% in moderate disease activity (ModDA) at baseline. Approximately twice as many patients in ModDA at baseline reached REM/LDA at week 52 vs those in HDA (61.7% vs 28.2%). Achieving cDAPSA treatment targets was associated with reductions in articular (swollen/tender joints) and extraarticular (skin involvement, enthesitis, dactylitis, functional disability) disease activity. Similar treatment target achievement rates were observed in the subgroup with ≥ 1 extraarticular PsA manifestation (n = 126; ModDA: 66.7%, HDA: 32.2%).
Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. Resolution and/or near resolution of articular and/or extraarticular PsA manifestations was achieved by patients in REM/LDA at week 52. Consistent treatment target achievement was observed in patients with 1 or multiple extraarticular manifestations of active PsA.
Metrics
Details
- Title
- Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
- Creators
- Philip J Mease - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Arthur Kavanaugh - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Alexis Ogdie - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Alvin F Wells - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Martin Bergman - Drexel UniversityDafna D Gladman - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Sven Richter - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Lichen Teng - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Shauna Jardon - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.Josef S Smolen - This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, Lichen Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. Conflicts of Interest: PJM has received grant/research support from and served as a consultant for AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GlaxoSmithKline, Novartis, Pfizer, Sun, and UCB and has been a speaker for AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen Inc., AstraZeneca, Bristol Myers Squibb, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer and has served as a consultant to AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly and has served as a consultant and speaker for AbbVie, Alexion, Amgen Inc., Bristol Myers Squibb, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen Inc., Novartis, Pfizer, and Sanofi; has served a consultant for AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche and has served as a consultant and speaker for AbbVie, Amgen Inc., Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to: Dr. Philip J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122. Tel.: 206-386-2000. Email: pmease@philipmease.com.
- Publication Details
- Journal of rheumatology, v 49(7), pp 694-699
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000828607700008
- Scopus ID
- 2-s2.0-85133528748
- Other Identifier
- 991019168490204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology